HOPA Annual Conference

“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.

A Q&A with Karen Fancher, PharmD, associate professor of pharmacy practice at Duquesne University School of Pharmacy, on applying ethical principles to manage complex situations in oncology pharmacy.

A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.

According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.

Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.

As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.

In 4 posters presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024, researchers addressed pharmacists’ role in managing patients’ anticancer medications.

Off-label drug combinations are increasingly being used in cancer treatments, but there is the potential for overlapping or additive toxicities, explained a speaker at the 2023 HOPA Annual Conference.

During a session at the 2023 HOPA Annual Conference, Rebecca Champion, PharmD, BCOP, highlighted new therapies in the market for hematologic malignancies with a focus on bispecific antibodies and chimeric antigen receptor T-cell therapies.

Precision oncology is a growing, changing field.